Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | CD69 | Q07108 | 2/20 | 0.60 |
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17896578 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2CD69ELANECYP2C19EPHX2 | |
| SCHEMBL16133043 | 0.90 | SMN1; SMN2 (0.60) | SMN1; SMN2CD69ELANECYP2C19EPHX2 | |
| SCHEMBL17896563 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2CD69ELANECYP2C19EPHX2 | |
| SCHEMBL24116187 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2CD69ELANECYP2C19EPHX2 | |
| SCHEMBL16234209 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2CD69ELANECYP2C19EPHX2 | |
| SCHEMBL10197366 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2CD69ELANECYP2C19EPHX2 | |
| SCHEMBL10197363 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2CD69ELANECYP2C19LMNA | |
| SCHEMBL30831879 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2CD69ELANECYP2C19ALOX15 | |
| SCHEMBL1986392 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2CD69ELANECYP2C19ALOX15 | |
| SCHEMBL2113930 | 0.81 | PPARD (0.52) | SMN1; SMN2ALOX15LMNAPTGDR2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8993631-B2 | Method of treating contrast-induced nephropathy | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2014-11-13 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-0288305-B1 | DI-T-BUTYLPHENYL ALKYL AND BENZYL ETHERS | RIKER LABORATORIES, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0324917-B1 | LOW PLATE-OUT POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 1993-06-30 | — | — | EP | disclosed |
| US-4973731-A | Di-t-butylphenyl alkyl and benzyl ether nitriles | RIKER LABORATORIES, INC. (US) | 1990-11-27 | — | — | US | disclosed |
| US-4950782-A | Low plate-out polycarbonates | GENERAL ELECTRIC COMPANY (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0324917-A1 | Low plate-out polycarbonates | GENERAL ELECTRIC COMPANY (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4841015-A | Low plate-out polycarbonate end capped with phenoxy acetic acid | GENERAL ELECTRIC COMPANY (US) | 1989-06-20 | — | — | US | disclosed |
| EP-0288305-A1 | Di-t-butylphenyl alkyl and benzyl ethers | RIKER LABORATORIES, INC. (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | SMN1; SMN2 456/4885CD69 4395/4885ELANE 524/4885 |
| US-20140336194-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | SMN1; SMN2 3985/4885CD69 4032/4885ELANE 9/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | SMN1; SMN2 1020/4885CD69 4489/4885ELANE 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.